Based on these findings, we propose that the TRIM32-INSR to be a potential site for pharmacological interventions as an effective therapy in mitigating obesity-induced hepatic insulin resistance, associated fatty liver disease, and dyslipidemia. This evidence concerns the gene TRIM32 and Insulin resistance.